InVivoMab anti-human CD47 BE0019-1-R001mg from Bio X Cell

Product Specs
ItemInVivoMab anti-human CD47
CompanyBio X Cell
Price Pricing Info Supplier Page View Company Product Page
Catalog NumberBE0019-1-R001mg
Quantity1 mg
Applicationsin vitro CD47 neutralization, in vivo CD47 neutralization in human tumor xenograft models or humanized mice, Flow cytometry
ConcentrationLot specific,typically between 4-11 mg/ml
Conjugate/TagUnconjugated
ReactivityHuman
TargetCD47
IsotypeIgG1, κ
CloneB6.H12
Hostmouse
NCBI Full Gene NameCD47 molecule
NCBI Gene AliasesIAP, MER6, OA3
ClonalityMonoclonal
ImmunogenIntact CD47 purified from placenta
Antibody TypePrimary Antibody
Purity>95%, Determined by SDS-PAGE
FormatPBS, pH 7.0, Contains no stabilizers or preservatives
Research AreaApoptosis, Cancer Biology, Cell Migration & Adhesion, Immune Checkpoint Protein, Immunology, Neuroscience

Other available quantities: Available in 1, 5, 10, 25, 50, 100 mg and bulk sizes. Academic discount available.

Endotoxin: <2EU/mg (<0.002EU/µg), Determined by LAL gel clotting assay

39 Labombard Rd

Lebanon, NH 03766

United States

Phone: 1-866-787-3444

Email: customerservice@bxcell.com

(1) PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunityNatureMay 25, 2017Gordon SR, Maute RL, Dulken BW, Hutter G, George BM, McCracken MN, Gupta R, Tsai JM, Sinha R, Corey D, et al.

(2) Anti-CD47 antibody suppresses tumour growth and augments the effect of chemotherapy treatment in hepatocellular carcinomaLiver international : official journal of the International Association for the Study of the LiverMay 1, 2016Lo J, Lau EY, So FT, Lu P, Chan VS, Cheung VC, Ching RH, Cheng BY, Ma MK, Ng IO, et al.

(4) Antibody mediated therapy targeting CD47 inhibits tumor progression of hepatocellular carcinomaCancer lettersMay 1, 2015Xiao Z, Chung H, Banan B, Manning PT, Ott KC, Lin S, Capoccia BJ, Subramanian V, Hiebsch RR, Upadhya GA, et al.

(6) Anti-CD47 antibody-mediated phagocytosis of cancer by macrophages primes an effective antitumor T-cell responseProceedings of the National Academy of Sciences of the United States of AmericaJuly 2, 2013Tseng D, Volkmer JP, Willingham SB, Contreras-Trujillo H, Fathman JW, Fernhoff NB, Seita J, Inlay MA, Weiskopf K, Miyanishi M, et al.

InVivoMab anti-human CD47